Nature's Sunshine Products (NATR)
NASDAQ:NATR
Want to see NATR full AI Analyst Report?
Top Page
Nature's Sunshine Products
(NASDAQ:NATR)
Select Model
Select Model
Rating:68Neutral
Price Target:
$23.00
▼(-15.87% Downside)
Action:Reiterated
Date:05/09/26
The score is driven primarily by solid financial health (strong margins and low leverage) and a positive earnings outlook with reiterated 2026 growth/EBITDA guidance. This is tempered by weak near-term technical momentum and only mid-range valuation support, alongside cash-flow inconsistency and investment-driven near-term margin/FCF risks.
Positive Factors
High Gross Margins
Sustained ~73% gross margins indicate durable product-level profitability for a supplements manufacturer. High gross margin provides pricing power and buffer against input cost swings, supporting reinvestment in digital, R&D, and distribution while preserving long-term EBITDA potential.
Negative Factors
Inconsistent Cash Generation
Uneven operating and free cash flow over multiple years raises execution risk for funding strategic investments, inventory builds, and shareholder returns. Episodic cash weakness can force trade-offs between growth spend and margin protection, stressing liquidity planning.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
Sustained ~73% gross margins indicate durable product-level profitability for a supplements manufacturer. High gross margin provides pricing power and buffer against input cost swings, supporting reinvestment in digital, R&D, and distribution while preserving long-term EBITDA potential.
Read all positive factors
Nature's Sunshine Products (NATR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$374.21M
Dividend YieldN/A
Average Volume (3M)100.66K
Price to Earnings (P/E)18.7
Beta (1Y)0.55
Revenue Growth7.26%
EPS Growth104.70%
CountryUS
Employees819
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)1.11
Shares Outstanding17,584,871
10 Day Avg. Volume135,715
30 Day Avg. Volume100,655
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.41
Price to Sales (P/S)0.81
P/FCF Ratio13.47
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue0.63
Enterprise Value/Gross Profit0.87
Enterprise Value/Ebitda6.94
Forecast
1Y Price Target
$37.00Price Target Upside35.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.08
Revenue Forecast (FY)$507.70M
Nature's Sunshine Products Business Overview & Revenue Model
Company Description
Nature's Sunshine Products, Inc., a natural health and wellness company, primarily manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products ...
How the Company Makes Money
Nature’s Sunshine makes money primarily by selling health and wellness products (dietary supplements and personal care items) through its distribution network. A key revenue stream is product sales to and through independent distributors (and, whe...
Nature's Sunshine Products Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The call emphasized strong top-line and profitability momentum driven by digital growth, Autoship subscription adoption, and improved gross margins, alongside a clean balance sheet and a strategic vision for scaling to $1 billion in sales. Management reiterated 2026 guidance while warning that near-term headwinds (geopolitical uncertainty, temporary investment-related SG&A increases, a small operating cash outflow, and the unsustainability of some one-time growth spikes such as China Q1) could moderate short-term results. On balance, the company highlighted multiple durable growth drivers and long-term investment plans that outweigh the discussed risks.Positive Updates
Top-Line Growth
Net sales of $122.9 million, up 9% year-over-year (7% ex-FX); described as the company's strongest first quarter in history and its third largest quarter ever.
Negative Updates
China Growth Sustainability Risk
While China delivered very strong Q1 growth (management cited ~40% in Q1), leadership cautioned that this level of growth is unlikely to be repeated in the near term, signaling potential volatility in APAC contributions.
Read all updates
Q1-2026 Updates
Positive
Negative
Top-Line Growth
Net sales of $122.9 million, up 9% year-over-year (7% ex-FX); described as the company's strongest first quarter in history and its third largest quarter ever.
Read all positive updates
Company Guidance
Management reiterated full-year 2026 guidance of $500–$515 million in net sales (4–7% growth versus $480M in 2025) and adjusted EBITDA of $50–$54 million (up to ~19% YoY), while expecting gross margins to average around 73% for the year; they forecast quarterly SG&A of $45–$47 million for the remainder of 2026 as strategic technology and growth investments ramp in Q2–Q3 (which will temper near‑term EBITDA expansion). The guidance builds on a strong Q1 (net sales $122.9M, adjusted EBITDA $14.6M, gross margin 73.2% up 116 bps, operating income $9.5M or 7.8% of sales, GAAP EPS $0.28), robust regional momentum (North America Q1 sales $38.3M with digital +42% and new digital customers +60%, APAC $52.2M, Europe $26.4M), and a clean balance sheet (cash ~$87.6M, zero debt, inventory $67.1M); management reiterated expectations for continued mid‑ to high‑single‑digit growth in North America and mid‑single‑digit growth in Europe, flagged cautious assumptions around Iran-driven inflation, and noted the company’s longer‑term targets of $1 billion in sales and a 15% EBITDA margin.Nature's Sunshine Products Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
84
Very Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 489.79M | 480.14M | 454.36M | 445.32M | 421.91M | 444.08M |
| Gross Profit | 356.10M | 347.72M | 324.69M | 321.13M | 299.76M | 328.62M |
| EBITDA | 44.51M | 43.75M | 32.79M | 32.09M | 31.15M | 43.23M |
| Net Income | 19.89M | 19.52M | 7.70M | 15.08M | -390.00K | 28.85M |
Balance Sheet | ||||||
| Total Assets | 261.46M | 261.15M | 240.85M | 249.77M | 229.78M | 258.87M |
| Cash, Cash Equivalents and Short-Term Investments | 87.58M | 93.89M | 84.70M | 82.37M | 60.03M | 86.18M |
| Total Debt | 22.43M | 18.90M | 14.20M | 14.92M | 19.18M | 22.99M |
| Total Liabilities | 94.54M | 99.59M | 79.86M | 90.23M | 82.73M | 97.47M |
| Stockholders Equity | 166.92M | 161.55M | 155.31M | 154.06M | 142.91M | 158.20M |
Cash Flow | ||||||
| Free Cash Flow | 23.02M | 28.84M | 14.33M | 30.75M | -6.92M | 27.94M |
| Operating Cash Flow | 30.87M | 35.32M | 25.30M | 41.23M | 710.00K | 34.61M |
| Investing Cash Flow | -14.01M | -12.64M | -10.97M | -10.48M | -7.63M | -6.61M |
| Financing Cash Flow | -18.46M | -17.61M | -9.90M | -7.96M | -16.25M | -31.72M |
Nature's Sunshine Products Technical Analysis
Negative
27.34
Price Trends
24.63
Negative
24.86
Negative
21.33
Negative
Market Momentum
-1.09
Positive
24.80
Positive
30.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NATR, the sentiment is Negative. The current price of 27.34 is above the 20-day moving average (MA) of 23.07, above the 50-day MA of 24.63, and above the 200-day MA of 21.33, indicating a bearish trend. The MACD of -1.09 indicates Positive momentum. The RSI at 24.80 is Positive, neither overbought nor oversold. The STOCH value of 30.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NATR.
Nature's Sunshine Products Risk Analysis
Nature's Sunshine Products disclosed 25 risk factors in its most recent earnings report. Nature's Sunshine Products reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nature's Sunshine Products Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $374.21M | 18.74 | 12.30% | ― | 7.26% | 104.70% | |
64 Neutral | $99.29M | 17.27 | 17.78% | 2.81% | -12.15% | -38.04% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
60 Neutral | $1.24B | 5.18 | -43.03% | ― | 3.69% | -16.34% | |
54 Neutral | $337.87M | 37.94 | 2.03% | ― | 5.67% | -73.96% | |
44 Neutral | $15.94M | -1.06 | -17.43% | ― | 12.37% | -69.61% |
* Consumer Defensive Sector Average
NATR
Nature's Sunshine Products
21.28
7.24
51.57%
HLF
Herbalife
11.96
4.26
55.32%
NAII
Natural Alternatives International
2.54
-0.79
-23.77%
USNA
USANA Health
18.30
-10.93
-37.39%
LFVN
LifeVantage
7.87
-4.33
-35.51%
Nature's Sunshine Products Corporate Events
Executive/Board Changes
Nature’s Sunshine Appoints Interim Principal Financial Officer
Neutral
May 11, 2026
On May 8, 2026, Nature’s Sunshine Products’ Chief Financial Officer and Principal Financial Officer, L. Shane Jones, notified the company that he would resign effective June 5, 2026, with the company stating that his departure did not ...
Business Operations and StrategyShareholder Meetings
Nature’s Sunshine Shareholders Approve 2026 Stock Incentive Plan
Positive
May 8, 2026
At its Annual Meeting of Shareholders on May 6, 2026, Nature’s Sunshine Products, Inc. secured shareholder approval for its 2026 Stock Incentive Plan, authorizing up to 1,500,000 shares of common stock for equity-based awards to employees, d...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Nature’s Sunshine Reports Strong Q4 and 2025 Results
Positive
Mar 11, 2026
Nature’s Sunshine reported strong results for the fourth quarter and full year ended December 31, 2025, with Q4 net sales up 4.7% to $123.8 million and gross margin improving to 72.5% on cost savings and favorable market mix. GAAP net income...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.